Saphenous Nerve Block for Foot and Ankle Surgery
Launched by UNIVERSITY OF BRITISH COLUMBIA · Mar 2, 2015
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
Purpose / Hypothesis This clinical study is a prospective, controlled, randomized, single-blinded trial designed to investigate the hypothesis that ultrasound-guided blockade of the saphenous nerve in conjunction with nerve stimulation has a higher success rate when compared to ultrasound alone. These research interventions represent what is considered to be an improvement on the standard practice at St. Paul's, which is to block the saphenous nerve with one of any number of saphenous nerve blocks, using a number of different techniques (i.e. ultrasound-guided, nerve stimulation, blind fiel...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects undergoing foot and ankle surgery
- • 2. Aged 19-80
- • 3. Normal sensation in saphenous nerve distribution in both legs
- • 4. Provided written informed consent.
- • 5. Body Mass Index \<38 kg/m2
- Exclusion Criteria:
- • 1. Subject refusal
- • 2. A known history of allergy, sensitivity or any other form of reaction to local anesthetics of amide type
- • 3. Suspected inability to comply with study procedures, including language difficulties or medical history and/or concomitant disease (i.e. skin infection as the site of needle insertion), as judged by the investigator. Reason for exclusion will be recorded.
- • 4. A neurological and/or vascular condition, which may preclude eligibility for peripheral nerve blockade (i.e. peripheral neuropathy) as judged by the investigator. Reason for exclusion will be recorded.
- • 5. Subjects on therapeutic anticoagulation or coagulopathy at the time of nerve blockade.
- • 6. Previous inclusion in this study.
- • 7. Participation in other clinical studies during this study or in the 14 days prior to admission to this study.
- • 8. Surgeon refusal (e.g. the surgeon does not want a nerve block for the subject). Reason for exclusion will be recorded.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Scott Bell, MD
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials